Corvus Pharmaceuticals 3Q Loss/Shr 22c >CRVS

Corvus Pharmaceuticals reported a third-quarter 2026 net loss of $20.3 million, compared with $10.2 million a year earlier. Cash, cash equivalents and marketable securities totaled $202.9 million at September 30, 2026, which the company expects to fund operations into the second quarter of 2028. Th…